NEW YORK – Oppenheimer on Thursday initiated coverage of molecular diagnostic firm DermTech with an Outperform rating and a share price target of $53.
In a note to investors, Oppenheimer analyst Kevin DeGeeter said the firm conducted a survey of 30 dermatology professionals to understand barriers to the test's adoption, demographic profiles of users versus non-users, and views about the use of genomic assays for identifying skin cancer.